On September 11, 2026 Phio Pharmaceuticals Corp. (NASDAQ: PHIO), a clinical-stage biotechnology company developing therapeutics based on its proprietary INTASYL siRNA gene-silencing technology designed to eliminate cancer, reported that members of its management team will be available for one-on-one investor meetings at the H.C. Wainwright 28th Annual Global Investment Conference, taking place September 14-16, 2026, at the Lotte New York Palace Hotel in New York City.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Robert Bitterman, President and Chief Executive Officer, and Lisa Carson, Chief Financial Officer, will be available for meetings with investors throughout the conference. At the conference, management will discuss the Company’s clinical lead candidate PH-762, strategic priorities, and upcoming initiatives designed to support continued execution and long-term value creation.

Phio Pharmaceuticals’ Presentation
A webcast of Phio Pharmaceuticals’ presentation is available through the following link: Journey

Conference Details
Event: H.C. Wainwright 28th Annual Global Investment Conference
Dates: September 14-16, 2026
Location: Lotte New York Palace Hotel, New York, NY

(Press release, Phio Pharmaceuticals, SEP 11, 2026, https://phiopharma.com/phio-pharmaceuticals-to-participate-in-the-h-c-wainwright-28th-annual-global-investment-conference/ [SID1234670758])